| Primary |
| Drug Use For Unknown Indication |
39.3% |
| Prophylaxis |
8.0% |
| Product Used For Unknown Indication |
7.1% |
| B-cell Unclassifiable Lymphoma High Grade |
5.4% |
| Non-hodgkin's Lymphoma |
5.4% |
| Hyperuricaemia |
4.5% |
| B-cell Lymphoma |
3.6% |
| Chronic Lymphocytic Leukaemia |
3.6% |
| Gouty Arthritis |
3.6% |
| Acute Myeloid Leukaemia |
2.7% |
| Mantle Cell Lymphoma |
2.7% |
| Stem Cell Transplant |
2.7% |
| Urinary Tract Infection |
2.7% |
| Hyperkalaemia |
1.8% |
| Klebsiella Infection |
1.8% |
| Prophylaxis Against Transplant Rejection |
1.8% |
| Agranulocytosis |
0.9% |
| Blood Uric Acid Increased |
0.9% |
| Gout |
0.9% |
| Hypothyroidism |
0.9% |
|
| Hepatitis Cholestatic |
10.7% |
| Drug Ineffective |
7.1% |
| Mental Impairment |
7.1% |
| Prothrombin Time Shortened |
7.1% |
| Renal Failure Acute |
7.1% |
| Thrombocytopenia |
7.1% |
| Thrombotic Thrombocytopenic Purpura |
7.1% |
| Bone Marrow Failure |
3.6% |
| Bronchospasm |
3.6% |
| Cerebrovascular Accident |
3.6% |
| Cytolytic Hepatitis |
3.6% |
| Death |
3.6% |
| Incorrect Drug Administration Rate |
3.6% |
| Intestinal Ischaemia |
3.6% |
| Ischaemic Stroke |
3.6% |
| Jaundice |
3.6% |
| Malaise |
3.6% |
| Methaemoglobinaemia |
3.6% |
| Nephritis Interstitial |
3.6% |
| Off Label Use |
3.6% |
|
| Secondary |
| Product Used For Unknown Indication |
39.9% |
| Drug Use For Unknown Indication |
15.0% |
| Acute Myeloid Leukaemia |
7.6% |
| B-cell Lymphoma |
4.9% |
| Prophylaxis |
4.4% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| T-cell Prolymphocytic Leukaemia |
3.0% |
| Acute Leukaemia |
2.7% |
| Premedication |
2.5% |
| Vomiting |
2.3% |
| Klebsiella Infection |
2.1% |
| Chronic Lymphocytic Leukaemia |
1.9% |
| Depression |
1.7% |
| Diarrhoea |
1.5% |
| Cardiac Failure |
1.3% |
| Mantle Cell Lymphoma |
1.3% |
| Non-obstructive Cardiomyopathy |
1.3% |
| Peripheral T-cell Lymphoma Unspecified |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.3% |
| Stem Cell Transplant |
1.3% |
|
| Hypertriglyceridaemia |
13.7% |
| Encephalopathy |
7.8% |
| Incorrect Drug Administration Rate |
7.8% |
| Toxic Epidermal Necrolysis |
7.8% |
| Aplasia |
5.9% |
| Death |
5.9% |
| Hepatic Steatosis |
5.9% |
| Pancreatitis Acute |
5.9% |
| Tumour Lysis Syndrome |
5.9% |
| Hepatotoxicity |
3.9% |
| Intestinal Ischaemia |
3.9% |
| Methaemoglobinaemia |
3.9% |
| Respiratory Failure |
3.9% |
| Supraventricular Tachycardia |
3.9% |
| Thrombocytopenia |
3.9% |
| Convulsion |
2.0% |
| Cytolytic Hepatitis |
2.0% |
| Dermatitis Bullous |
2.0% |
| Haemolytic Anaemia |
2.0% |
| Hypersensitivity |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.6% |
| Acute Lymphocytic Leukaemia |
11.2% |
| Acute Myeloid Leukaemia |
9.9% |
| Drug Use For Unknown Indication |
9.9% |
| Pyrexia |
8.9% |
| Hodgkin's Disease |
6.9% |
| Prophylaxis |
6.2% |
| Mantle Cell Lymphoma |
4.6% |
| Prophylaxis Of Nausea And Vomiting |
3.2% |
| Hyperuricaemia |
2.9% |
| B-cell Lymphoma |
2.4% |
| Aspergillosis |
2.2% |
| Pain |
2.2% |
| Antifungal Prophylaxis |
2.0% |
| Hiv Infection |
2.0% |
| Haematological Malignancy |
1.7% |
| Wound Complication |
1.7% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Premedication |
1.6% |
| Antiviral Prophylaxis |
1.3% |
|
| Bacterial Sepsis |
11.3% |
| Photosensitivity Reaction |
9.9% |
| Tremor |
9.9% |
| Fasciitis |
7.0% |
| Nervous System Disorder |
5.6% |
| Pyrexia |
5.6% |
| Renal Failure Acute |
5.6% |
| Condition Aggravated |
4.2% |
| Hemiplegia |
4.2% |
| Pancreatitis Acute |
4.2% |
| Septic Shock |
4.2% |
| Thrombocytopenia |
4.2% |
| Weight Decreased |
4.2% |
| Coma |
2.8% |
| Dermatitis Exfoliative |
2.8% |
| Escherichia Infection |
2.8% |
| Febrile Neutropenia |
2.8% |
| Hallucination, Auditory |
2.8% |
| Hepatocellular Injury |
2.8% |
| Hypophosphataemia |
2.8% |
|
| Interacting |
| Drug Use For Unknown Indication |
53.5% |
| Non-hodgkin's Lymphoma |
46.5% |
|
|
